Gastrointestinal disease holds cell therapy's strongest regulatory milestone.
If you want proof that this field can meet the highest evidentiary bar, it is here. A stem cell therapy for a complication of Crohn's disease passed a phase 3 randomized controlled trial published in a leading medical journal and earned regulatory approval in multiple countries.
That story, including its complicated second chapter, tells you more about how to judge this field than any marketing page. Here is all of it.
Aurenza does not claim that regenerative medicine treats, cures, or reverses any gastrointestinal condition.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What the Research Shows
If you want proof this field can clear the highest evidentiary bar that exists, it is here: a stem cell therapy that passed a phase 3 randomized controlled trial in a leading medical journal and earned regulatory approval in multiple countries.
The ADMIRE-CD trial, published in The Lancet (2016), was a phase 3, randomised, double-blind, controlled trial of expanded allogeneic adipose-derived stem cells injected locally for complex perianal fistulas in Crohn's disease. It demonstrated statistically significant superiority over control for combined remission at 24 weeks, confirmed by MRI, with the effect maintained at week 52. Long-term follow-up in Gastroenterology (2018) and a 104-week extension in Diseases of the Colon and Rectum reported a safety profile comparable to control with remission that may be sustained long term.
On that evidence, the therapy, darvadstrocel, was approved in the European Union, the United Kingdom, Switzerland, Israel, and Japan for complex perianal fistulas in adults with Crohn's disease after inadequate response to prior therapy: the first allogeneic stem cell therapy to receive centralized EU marketing authorization. Real-world programs keep studying it, including the INSPECT long-term effectiveness study in Inflammatory Bowel Diseases and a national implementation study registered on ClinicalTrials.gov. Beyond fistulas, pooled randomized data across inflammatory bowel disease favored MSC groups on clinical efficacy.
The Honest Line
This story has a complicated second chapter, and you get all of it. In 2023 the larger confirmatory trial, ADMIRE-CD II, did not meet its primary endpoint, with full results published in Gastroenterology and the sponsor's own topline disclosure reporting remission rates high in both arms, roughly 41% with cells versus 40% with placebo, where the comparator included surgical fistula preparation that itself performed far better than expected. The therapy remained well tolerated with no new safety signals. Both trials are real: one supported approvals across multiple regulatory systems, one failed on a larger stage. That is how evidence actually works, and no study shows a guarantee it works every time, or that it will work for you. The approval also covers one specific complication of Crohn's disease delivered by local injection; it says nothing about IBS, general gut health, or systemic infusions for digestive complaints.
Why This Is Exactly Where a Candidacy Review Comes In
Whether the strong end of this evidence speaks to you comes down to your actual diagnosis, your disease activity, and your current treatment, which is exactly the file a review is built from, in coordination with your gastroenterologist. Every trial above produced its results in selected patients who met specific criteria. That is the gap between "documented in research" and "right for you," and it is the gap a candidacy review exists to close. Before anything is recommended, your bloodwork, biomarkers, imaging, and history are reviewed by a physician panel to establish whether you are actually in the population the research describes. If the picture supports moving forward, you will know exactly why. If it does not, you will be told that, plainly. That is where to start.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What Your Candidacy Review Covers
What to Ask Any Provider
Does the evidence you are citing match my actual diagnosis and its complications, or a different one? Are you coordinating with my gastroenterologist? What is being administered, from what source, at what verified cell count, and by what route? What would make me a poor candidate? What does the strongest trial against your recommendation say?
The Honest Limits
Individual results cannot be predicted or guaranteed. No stem cell therapy is FDA approved in the United States for gastrointestinal conditions, and procedures coordinated by Aurenza take place in Mexico under COFEPRIS regulation. Never stop or change prescribed IBD therapy except under the direction of your treating specialist.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
Free consultation with a care consultant, many of whom are registered nurses. No sales reps. No receptionist.